作者
Dung T Le, Andrea Wang-Gillam, Vincent Picozzi, Tim F Greten, Todd Crocenzi, Gregory Springett, Michael Morse, Herbert Zeh, Deirdre Cohen, Robert L Fine, Beth Onners, Jennifer N Uram, Daniel A Laheru, Eric R Lutz, Sara Solt, Aimee Luck Murphy, Justin Skoble, Ed Lemmens, John Grous, Thomas Dubensky Jr, Dirk G Brockstedt, Elizabeth M Jaffee
发表日期
2015/4/4
期刊
Journal of clinical Oncology
卷号
33
期号
12
页码范围
1325
出版商
American Society of Clinical Oncology
简介
Purpose
GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhibit regulatory T cells. CRS-207, live-attenuated Listeria monocytogenes–expressing mesothelin, induces innate and adaptive immunity. On the basis of preclinical synergy, we tested prime/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
学术搜索中的文章
DT Le, A Wang-Gillam, V Picozzi, TF Greten… - Journal of clinical Oncology, 2015